EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Mechanical Thrombectomy Versus Anticoagulation Alone in Intermediate-High Risk PE

Rachel P Rosovsky, Stavros V Konstantinides, Ido Weinberg, Suhail Y Dohad, Zachary Rosol, Jakub Stępniewski, John M Moriarty, Sahil A Parikh, Andrew Holden, Richard N Channick, Braedon McDonald, Khanjan H Nagarsheth und 3 weitere

JACC: Cardiovascular Interventions · 2026

DOI: 10.1016/j.jcin.2026.07.042 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2026. Verfasst von Rachel P Rosovsky und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. E…. Hauptthemen laut MEDLINE: Anticoagulants, Pulmonary Embolism, Thrombectomy, Fibrinolytic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Penumbra Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Up to 50% of pulmonary embolism (PE) survivors experience long-term functional limitations and reduced quality of life (QoL). Reperfusion strategies can rapidly relieve right-ventricular (RV) dysfunction and prevent clinical deterioration or hemodynamic collapse; however, these approaches have never been evaluated in a randomized trial against anticoagulation alone using patient-centered outcomes. OBJECTIVES: This study sought to evaluate whether mechanical thrombectomy with anticoagulation improves functional, QoL, and safety outcomes compared with anticoagulation alone in patients with acute intermediate-high risk PE over 90 days. METHODS: STORM-PE enrolled 100 PE patients randomized 1:1 to computer-assisted vacuum thrombectomy (CAVT) with anticoagulation or anticoagulation alone across 22 international sites, with RV-to-left-ventricular (RV/LV) ratio change at 48 hours as the primary endpoint. Secondary endpoints included major adverse events within 7 days, functional and QoL outcomes, mortality, and symptomatic PE recurrence through 90 days. RESULTS: For all patients, median time from randomization to last follow-up visit was 91.0 days [Q1-Q3: 80.5-100.0]. At 90 days, 66.0% (31/47) of CAVT and 64.2% (34/53) of anticoagulation patients completed the 6-min walk test. The CAVT arm exhibited a longer 6-min walk distance compared with anticoagulation alone (478.7 ± 159.5 m vs 368.0 ± 127.8 m, P = 0.003). More CAVT than anticoagulation patients were NYHA functional class I (97.4% [37/38] vs 75.6% [34/45], P = 0.005) at 90 days. Dyspnea and QoL scores were comparable between groups, with no differences between arms for all-cause mortality, PE-related mortality, and symptomatic PE recurrence within 90 days. CONCLUSIONS: In STORM-PE, CAVT with anticoagulation resulted in improved functional outcomes at 90 days compared with anticoagulation alone, with equivalent safety rates. This trial supports CAVT as an effective and safe reperfusion strategy for intermediate-high risk PE. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov Unique Identifier: NCT05684796.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsPulmonary EmbolismThrombectomyFibrinolytic AgentsHumansTime FactorsTreatment OutcomeFemaleRecovery of FunctionRisk FactorsMaleQuality of LifeAgedRecurrenceFunctional StatusMiddle AgedVentricular Function, RightVentricular Function, LeftRisk AssessmentExercise Tolerance

Stichwörter der Autor:innen

anticoagulantsfunctional statuspulmonary embolismrandomized controlled trialthrombectomy

Substanzen

AnticoagulantsFibrinolytic Agents

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. Electronic address: rprosovsky@mgh.harvard.edu.
  • Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany; Department of Cardiology, Democritus University of Thrace, Alexandroupolis, Greece.
  • Vascular Medicine, Massachusetts General Brigham, Boston, Massachusetts, USA.
  • Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, California, USA.
  • Interventional Cardiology, Baylor University Medical Center/ The Heart Hospital Medical Group, The Heart Hospital, Dallas, Intensive Care Unit, Texas A&M Health Science Center, Dallas, Texas, USA.
  • Pulmonary Circulation Centre, Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, Krakow, Poland; Department of Cardiac and Vascular Diseases, St John Paul II Hospital, Krakow, Poland.

Förderung

  • Penumbra Inc

Zitieren

APA

Rosovsky, R. P., Konstantinides, S. V., Weinberg, I., Dohad, S. Y., Rosol, Z., Stępniewski, J., Moriarty, J. M., Parikh, S. A., Holden, A., Channick, R. N., McDonald, B., Nagarsheth, K. H., Matusov, Y., Lookstein, R. A., & STORM-PE Trial Investigators and Collaborators (2026). Mechanical Thrombectomy Versus Anticoagulation Alone in Intermediate-High Risk PE. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2026.07.042

Vancouver

Rosovsky RP, Konstantinides SV, Weinberg I, Dohad SY, Rosol Z, Stępniewski J, et al. Mechanical Thrombectomy Versus Anticoagulation Alone in Intermediate-High Risk PE. JACC: Cardiovascular Interventions. 2026. doi:10.1016/j.jcin.2026.07.042

BibTeX
@article{Rosovsky2026,
  author = {Rosovsky, Rachel P and Konstantinides, Stavros V and Weinberg, Ido and Dohad, Suhail Y and Rosol, Zachary and Stępniewski, Jakub and Moriarty, John M and Parikh, Sahil A and Holden, Andrew and Channick, Richard N and McDonald, Braedon and Nagarsheth, Khanjan H and Matusov, Yuri and Lookstein, Robert A and STORM-PE Trial Investigators and Collaborators, STORM-PE Trial Investigators and Collaborators},
  title = {Mechanical Thrombectomy Versus Anticoagulation Alone in Intermediate-High Risk PE},
  journal = {JACC: Cardiovascular Interventions},
  year = {2026},
  doi = {10.1016/j.jcin.2026.07.042}
}
Kostenlos starten →